By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Tarix Pharmaceuticals 



Brookline  Massachusetts    U.S.A.
Phone: 617-827-6824 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Tarix Pharmaceuticals Orphan Receives FDA Fast Track Designation For TXA127 As Potential Treatment For Duchenne Muscular Dystrophy 10/6/2015 6:46:17 AM
Tarix Pharmaceuticals' Peptide Technology Stimulates Revascularization Following Ischemia 3/5/2013 10:27:53 AM
Unigene Laboratories, Inc. (UGNE) and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127 11/27/2012 8:59:03 AM
Unigene Laboratories, Inc. (UGNE) and Tarix Pharmaceuticals Report Highly Increased Oral Bioavailability of "Peptelligence-Engineered" TXA127 9/19/2012 10:25:46 AM
Tarix Pharmaceuticals' TXA127 Granted Orphan Drug Status for Treatment of Pulmonary Arterial Hypertension 9/27/2011 10:17:43 AM
Tarix Pharmaceuticals Enrolls First Patient in Phase 1 Clinical Study of TXA127 in Adult Patients Following Double Cord Blood Stem Cell Transplant 4/26/2011 6:52:17 AM
Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant 2/24/2011 7:36:54 AM
//-->